Dr. Jon E. Arnason, MD
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 22
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 230
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
NY license 245246
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Beth Israel Deaconess Medical Center Boston, MA
- Beth Israel Deaconess Hospital Plymouth Plymouth, MA
Medical groups
- Harvard Medical Faculty Phys at Beth Israel Deaconess Med Ctr Inc (1,740 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 230
- Services billed
- 794
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 364 | 150 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 320 | 72 |
| Established patient office or other outpatient visit, 40-54 minutes | 184 | 42 |
| Telephone medical discussion with physician, 11-20 minutes | 25 | 19 |
| Hospital discharge day management, 30 minutes or less | 22 | 22 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in New York, NY | 36 |
| Calquence (acalabrutinib maleate) | 20 |
| Tamsulosin Hcl Other prescribers in New York, NY | 14 |
| Prednisone Other prescribers in New York, NY | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 10 payments worth $7,396 in total to this clinician.
| Regeneron Pharmaceuticals, Inc. | $6,644 |
|---|---|
| Celgene Corporation | $715 |
| Janssen Biotech, Inc. | $37.09 |
| Consulting Fee | $6,536 |
|---|---|
| Travel and Lodging | $715 |
| Food and Beverage | $146 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. May 30, 2025 | Consulting Fee | $2,043 |
| Regeneron Pharmaceuticals, Inc. Dec 19, 2025 | Consulting Fee | $2,043 |
| Regeneron Pharmaceuticals, Inc. May 30, 2025 | Consulting Fee | $817 |
| Regeneron Pharmaceuticals, Inc. Dec 19, 2025 | Consulting Fee | $817 |
| Regeneron Pharmaceuticals, Inc. May 30, 2025 | Consulting Fee | $409 |
| Regeneron Pharmaceuticals, Inc. Dec 19, 2025 | Consulting Fee | $409 |
| Celgene Corporation Sep 30, 2025 | Travel and Lodging travel to Philadelphia, PA | $379 |
| Celgene Corporation Sep 29, 2025 | Travel and Lodging travel to Philadelphia, PA | $336 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $304,690 in research payments for these studies, mostly to the institutions running them.
- A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT02028455 - A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT03888105 - Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release
Celgene Corporation - A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
Beone Medicines Ltd. · Active, not recruiting · NCT04002297
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.